Recursion Pharmaceuticals RXRX
NASDAQ RXRX
$4.13 +0.10 (+2.48%)
At close: Sep 30, 2026 · 4:00 PM EDT

Recursion Pharmaceuticals (RXRX) Long-Term Deferred Tax (2024 - 2026)

Updated

Recursion Pharmaceuticals (RXRX) reported Long-Term Deferred Tax of $957,000 for Q2 2026, unchanged from $957,000 a year earlier and unchanged from the prior quarter.

Analysis

Recursion Pharmaceuticals (RXRX) Long-Term Deferred Tax (2024 - 2026) Analysis & Trends

Dating back to Q4 2024, Recursion Pharmaceuticals' Long-Term Deferred Tax record includes 7 quarters.

  • By year, Long-Term Deferred Tax came in at $1.93 million in FY2024.
  • Five-year quarterly Long-Term Deferred Tax spans a low of $957,000 in Q2 2025 and a high of $2 million in Q1 2025.
  • Per Business Quant data, the three quarters before Q2 2026 came in at $957,000 (Q1 2026), $957,000 (Q4 2025) and $957,000 (Q3 2025).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Johnson & Johnson 638.12 Bn 556.64 Bn 17.26 Bn
2 AbbVie 462.60 Bn 435.75 Bn 12.70 Bn
3 Merck 358.70 Bn 313.13 Bn 12.21 Bn
4 Novartis Ag 272.16 Bn 228.03 Bn 11.24 Bn
5 Astrazeneca 250.36 Bn 223.92 Bn 12.86 Bn
6 Amgen 227.87 Bn 183.27 Bn 7.24 Bn
7 Gilead Sciences 184.97 Bn 159.08 Bn 6.22 Bn
8 Pfizer 162.61 Bn 109.56 Bn 10.94 Bn
9 Vertex Pharmaceuticals 132.45 Bn 104.46 Bn 2.84 Bn
10 Recursion Pharmaceuticals 2.21 Bn -397.37 Mn -3.82 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 957,000.00
Mar 31, 2026 957,000.00
Dec 31, 2025 957,000.00
Sep 30, 2025 957,000.00
Jun 30, 2025 957,000.00
Mar 31, 2025 2.00 Mn
Dec 31, 2024 1.93 Mn
API Access

Recursion Pharmaceuticals Long-Term Deferred Tax API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=long-term-deferred-tax&ticker=RXRX&period=max&api_key=YOUR_API_KEY